HK1048254B - 製造可持續釋放的麥角生物鹼製藥成分 (其生物藥效率及成分經改良) 的方法 - Google Patents

製造可持續釋放的麥角生物鹼製藥成分 (其生物藥效率及成分經改良) 的方法

Info

Publication number
HK1048254B
HK1048254B HK03100375.2A HK03100375A HK1048254B HK 1048254 B HK1048254 B HK 1048254B HK 03100375 A HK03100375 A HK 03100375A HK 1048254 B HK1048254 B HK 1048254B
Authority
HK
Hong Kong
Prior art keywords
compositions
bioavailability
sustained
methods
ergot
Prior art date
Application number
HK03100375.2A
Other languages
English (en)
Other versions
HK1048254A1 (en
Inventor
Mailland Federico
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of HK1048254A1 publication Critical patent/HK1048254A1/xx
Publication of HK1048254B publication Critical patent/HK1048254B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK03100375.2A 1999-12-03 2003-01-15 製造可持續釋放的麥角生物鹼製藥成分 (其生物藥效率及成分經改良) 的方法 HK1048254B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45436499A 1999-12-03 1999-12-03
PCT/EP2000/012302 WO2001039742A2 (en) 1999-12-03 2000-11-30 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof

Publications (2)

Publication Number Publication Date
HK1048254A1 HK1048254A1 (en) 2003-03-28
HK1048254B true HK1048254B (zh) 2005-06-03

Family

ID=23804314

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100375.2A HK1048254B (zh) 1999-12-03 2003-01-15 製造可持續釋放的麥角生物鹼製藥成分 (其生物藥效率及成分經改良) 的方法

Country Status (17)

Country Link
US (1) US20020114836A1 (zh)
EP (2) EP1512403A1 (zh)
JP (1) JP4965784B2 (zh)
KR (1) KR100504618B1 (zh)
CN (1) CN100400042C (zh)
AT (1) ATE288269T1 (zh)
AU (1) AU2165301A (zh)
BR (1) BR0016084A (zh)
CA (1) CA2393344C (zh)
DE (1) DE60017938T2 (zh)
ES (1) ES2236017T3 (zh)
HK (1) HK1048254B (zh)
MX (1) MXPA02005291A (zh)
PL (1) PL202357B1 (zh)
PT (1) PT1235574E (zh)
RU (1) RU2256454C2 (zh)
WO (1) WO2001039742A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520390A (ja) * 2003-03-14 2006-09-07 ムルイェ、ニルマル 徐放性錠剤の製造方法
TW200517106A (en) * 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
EP1904067B2 (en) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
CN101590058B (zh) * 2009-07-02 2011-04-27 苏州东瑞制药有限公司 含有甲磺酸二氢麦角隐亭a的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
BE880713A (fr) * 1978-12-21 1980-06-19 Sandoz Sa Nouvelles compositions pharmaceutiques solides a base d'alcaloides de l'ergot de seigle, permettant une liberation controlee de ce principe actif
JPS615010A (ja) * 1984-06-18 1986-01-10 Tooa Eiyoo Kk 水素添加麦角アルカロイド徐放性製剤及びその製法
HU195729B (en) * 1985-02-05 1988-07-28 Sandoz Ag Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
SI8710406B (sl) * 1987-03-11 1998-08-31 Lek Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications

Also Published As

Publication number Publication date
EP1235574B1 (en) 2005-02-02
CA2393344C (en) 2009-09-01
KR20020063197A (ko) 2002-08-01
DE60017938T2 (de) 2006-01-12
EP1235574A2 (en) 2002-09-04
US20020114836A1 (en) 2002-08-22
ES2236017T3 (es) 2005-07-16
WO2001039742A3 (en) 2001-12-13
JP2003515549A (ja) 2003-05-07
DE60017938D1 (de) 2005-03-10
PL356387A1 (en) 2004-06-28
JP4965784B2 (ja) 2012-07-04
AU2165301A (en) 2001-06-12
RU2256454C2 (ru) 2005-07-20
PT1235574E (pt) 2005-05-31
RU2002117655A (ru) 2004-01-27
HK1048254A1 (en) 2003-03-28
PL202357B1 (pl) 2009-06-30
ATE288269T1 (de) 2005-02-15
CA2393344A1 (en) 2001-06-07
EP1512403A1 (en) 2005-03-09
CN1433311A (zh) 2003-07-30
KR100504618B1 (ko) 2005-08-04
MXPA02005291A (es) 2004-06-21
WO2001039742A2 (en) 2001-06-07
BR0016084A (pt) 2002-08-06
CN100400042C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
US6358527B1 (en) Fast-dissolving galanthamine hydrobromide tablet
CA1147651A (en) Sustained release pharmaceutical compositions
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
AU684053B2 (en) Compositions of L-DOPA esters
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
US4724148A (en) Amosulalol hydrochloride long acting formulation
HK1048254A1 (en) Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof.
CA2216277A1 (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
NO173736C (no) Analogifremgangsmaate for fremstilling av en terapeutisk aktiv forbindelse bestaaende hovedsaklig av diastereomer (I) av cefalosporinderivater
AU597570B2 (en) Pharmaceutical 9,10-dehydrogenated ergot alkaloid containing compositions
WO2019245309A1 (en) A sustained release pharmaceutical preparation comprising tacrolimus
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
PL328123A1 (en) Derivatives of banzo[c]quinolysine and method of obtaining them
WO1999005103A3 (en) 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent
DK0524696T3 (da) Orale præparater indeholdende dapiprazol
CA2180703A1 (en) Fast-dissolving galanthamine hydrobromide tablet
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
WO2024144207A1 (en) Sustained-release tablet comprising apixaban
JP2003504416A (ja) イオン交換樹脂を使用する経口キノロン液状製剤の味覚マスキング
SE9600791L (sv) Metod för eradikering av Helicobacter pylori infektion
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
MX9601033A (es) Nanosuspensiones para administracion intravenosa.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161130